We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
The report presents a review of etomidate and structurally related compounds and subsequent recommendations regarding their classification and scheduling.
ACMD Chair: Prof Owen Bowden-Jones NPS Committee Secretary: Yetunde…
1. Introduction Etomidate is a drug that has sedative effects and is used…
Sarah Jones MP Minister of State for Policing and Crime 2 Marsham Street…
This report considers the use, harms and control of carisoprodol, a muscle relaxant previously prescribed in the UK to treat muscle spasms.
1. Introduction 1.1. Carisoprodol is an orally active centrally acting…
Following a 2025 government commission, the ACMD has carried out a review of the use and harms of ketamine.
1. Introduction 1.1. Ketamine is a widely used human and veterinary…
ACMD Chair: Prof David Wood ACMD Ketamine Working Group Chair: Prof Simon…
Review of the evidence on the use and harms of xylazine, medetomidine and detomidine.
A review of the evidence on the use and harms of 2-benzyl benzimidazole (nitazene) and piperidine benzimidazolone (brorphine-like) opioids.
ACMD review into the use and harms of SSCs and THCA to identify compounds causing harm which are not captured by the current generic definition for cannabinoids.
Report on the long-term prevention of drug use and related harms among young people.
ACMD has written an updated harms assessment describing the use and harms of synthetic cathinones following a government commission.
The Advisory Council on the Misuse of Drugs has provided an updated harms assessment of alkyl nitrites.
A review of the evidence on the use, harms and prevalence of recently encountered uncontrolled novel benzodiazepines and related compounds (2024 update).
This report has considered the harms and control of 2-methyl-AP-237 and other closely related acyl piperazine opioids.
Recommendations from the ACMD to reduce barriers to research for schedule 1 controlled drugs.
Report from the Advisory Council on the Misuse of Drugs (ACMD) on consumer cannabidiol (CBD) products.
The Advisory Council on the Misuse of Drugs has undertaken a review of the availability and implementation of naloxone in the UK.
The Advisory Council on the Misuse of Drugs (ACMD) has provided advice on the scheduling of nitrous oxide.
This report provides an updated assessment of the health and social harms of nitrous oxide.
The Advisory Council on the Misuse of Drugs has undertaken a review of the evidence on the use and harms of Cumyl-PeGaClone.
The Advisory Council on the Misuse of Drugs has undertaken a review of the evidence on the use and harms of diphenidine and other related substances.
Recommendations to reduce barriers to research, using compounds described by the third generation synthetic cannabinoid receptor agonists generic definition.
This report provides an updated harms assessment to the ACMD's previous reports on synthetic cannabinoid receptor agonists.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab and requires JavaScript).